[1] |
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus[J]. Lancet, 2019,394(10201):882⁃894. doi: 10.1016/S0140⁃6736(19)31778⁃ 7.
|
[2] |
Porro AM, Caetano Lde V, Maehara Lde S, et al. Non⁃classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus[J]. An Bras Dermatol, 2014,89(1):96⁃106. doi: 10.1590/abd1806⁃4841.2014 2459.
|
[3] |
Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now[J]. J Am Acad Dermatol, 2014,70(4):780⁃787. doi: 10.1016/j.jaad.2013.11.043.
|
[4] |
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities[J]. Immunol Res, 2018,66(2):255⁃270. doi: 10.1007/s12026⁃018⁃8986⁃7.
|
[5] |
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts[J]. J Am Acad Dermatol, 2020,82(3):575⁃585.e1. doi: 10.1016/j.jaad.2018.02.021.
|
[6] |
McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid⁃sparing agents in the management of pemphigus: defining a niche for these low toxicity agents[J]. J Am Acad Dermatol, 2014,71(3):475⁃479. doi: 10.1016/j.jaad.2014.04.040.
|
[7] |
Boulard C, Duvert Lehembre S, Picard⁃Dahan C, et al. Calculation of cut⁃off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus[J]. Br J Dermatol, 2016,175(1):142⁃149. doi: 10.1111/bjd.14405.
|
[8] |
Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus[J]. J Am Acad Dermatol, 2008,58(6):1043⁃1046. doi: 10.1016/j.jaad.2008.01.012.
|
[9] |
中国医师协会皮肤科医师分会自身免疫疾病亚专业委员会.寻常型天疱疮诊断和治疗的专家建议[J]. 中华皮肤科杂志, 2016,49(11):761⁃765. doi: 10.3760/cma.j.issn.0412⁃4030.2016. 11.01.
|
[10] |
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0[S]. Bethesda Maryland: National Institutes of Health, 2017.
|
[11] |
Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2020,34(9):1900⁃1913. doi: 10.1111/jdv.16752.
|
[12] |
Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report[J]. Arch Dermatol, 1986,122(6):670⁃674.
|
[13] |
Garrido⁃Mesa N, Zarzuelo A, Gálvez J. What is behind the non⁃antibiotic properties of minocycline?[J]. Pharmacol Res, 2013,67(1):18⁃30. doi: 10.1016/j.phrs.2012.10.006.
|
[14] |
Li F, Wu Y, Bian W, et al. Features and associated factors of bacterial skin infections in hospitalized patients with pemphigus: a single⁃center retrospective study[J]. Ann Clin Microbiol Antimicrob, 2020,19(1):46. doi: 10.1186/s12941⁃020⁃00388⁃6.
|
[15] |
Bidell MR, Lodise TP. Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline[J]. Pharmacotherapy, 2021,41(11):915⁃931. doi: 10.1002/phar.2625.
|
[16] |
Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases[J]. J Am Acad Dermatol, 1993,28(6):998⁃1000. doi: 10.1016/s0190⁃9622(08)80651⁃2.
|
[17] |
Alpsoy E, Yilmaz E, Basaran E, et al. Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus?[J]. Arch Dermatol, 1995,131(11):1339⁃1340. doi: 10.1001/archderm.131.11.1339.
|
[18] |
McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid⁃sparing agents in the management of pemphigus: defining a niche for these low toxicity agents[J]. J Am Acad Dermatol, 2014,71(3):475⁃479. doi: 10.1016/j.jaad.2014.04.040.
|
[19] |
Dumas V, Roujeau JC, Wolkenstein P, et al. The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid[J]. Br J Dermatol, 1999,140(6):1127⁃1129. doi: 10.1046/j.1365⁃2133.1999.02895.x.
|
[20] |
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid[J]. N Engl J Med, 2002,346(5):321⁃327. doi: 10.1056/NEJMoa 011592.
|
[21] |
Ingen⁃Housz⁃Oro S, Valeyrie⁃Allanore L, Cosnes A, et al. First⁃line treatment of pemphigus vulgaris with a combination of rituximab and high⁃potency topical corticosteroids[J]. JAMA Dermatol, 2015,151(2):200⁃203. doi: 10.1001/jamadermatol. 2014.2421.
|
[22] |
Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non⁃inferiority, randomised controlled trial[J]. Lancet, 2017,389(10079):1630⁃1638. doi: 10.1016/S0140⁃6736(17)30560⁃3.
|
[23] |
Marzo⁃Ortega H, Baxter K, Strauss RM, et al. Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross⁃sectional study[J]. Br J Dermatol, 2007,156(5):1005⁃1009. doi: 10.1111/j.1365⁃2133.2007.07828.x.
|
[24] |
Rice JB, White AG, Scarpati LM, et al. Long⁃term systemic corticosteroid exposure: a systematic literature review[J]. Clin Ther, 2017,39(11):2216⁃2229. doi: 10.1016/j.clinthera. 2017. 09.011.
|
[25] |
Schoonen WM, Thomas SL, Somers EC, et al. Do selected drugs increase the risk of lupus? A matched case⁃control study[J]. Br J Clin Pharmacol, 2010,70(4):588⁃596. doi: 10.1111/j.1365⁃2125.2010.03733.x.
|